Skip to main content
SpringerLink
Log in

Nonfunctioning neuroendocrine pancreatic tumors: our experience and management

  • Original article
  • Published:
Journal of Hepato-Biliary-Pancreatic Surgery

Abstract

Background and purpose

We present our experience in the treatment of nonfunctioning neuroendocrine pancreatic tumors (NFNPTs) to define the clinical and pathological characteristics and to suggest proper management.

Methods

The records of 17 patients with NFNPTs operated on between 1998 and 2008 were retrospectively reviewed, and all tumors were classified clinicopathologically as benign, uncertain, and malignant, based on the World Health Organization (WHO) classification of neuroendocrine tumors.

Results

There were four benign, six uncertain, and seven malignant NFNPTs. The most frequent symptoms were abdominal pain (five patients) and obstructive jaundice (one patient). Most of these symptomatic patients had malignant tumors. Mean tumor size of benign, uncertain, and malignant tumors were 1.0 ± 0.3, 3.2 ± 1.6, and 5.3 ± 2.4 cm, respectively. Metastatic lesions of malignant tumors were lymph node (six patients), liver (four patients), and adrenal gland (one patient). Six of seven patients with malignant tumors underwent curative rejection. There were recurrences in four of six patients with curatively rejected malignant tumors. Two patients underwent more rejection, three patients received systemic chemotherapy, and two patients underwent radiofrequency ablation and transcatheter arterial chemoembolization for liver metastases. Survival of patients with malignant tumors was significantly shorter than that of patients with benign and uncertain tumors. However, three patients with malignant tumors had long survival of more than 3 years, even with metastases or recurrences.

Conclusions

Aggressive surgical resection should be performed in patients with resectable NFNPTs, even with metastases. Even when a tumor was unresectable or there were recurrences, long-time palliation could be achieved by a multidisciplinary approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Moldow RE, Conelly RR. Epidemiology of pancreatic cancer in Connecticut. Gastroenterology. 1968;55:677–86.

    PubMed  CAS  Google Scholar 

  2. Kent RB, van Heerden JA, Weiland LH. Nonfunctioning islet cell tumors. Ann Surg. 1981;193:185–90.

    Article  PubMed  Google Scholar 

  3. Broughan TA, Leslie JD, Soto JM, Hermann RE. Pancreatic islet tumors. Surgery. 1986;99:671–8.

    PubMed  CAS  Google Scholar 

  4. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch. 1995;425:547–60.

    Article  PubMed  CAS  Google Scholar 

  5. Klöppel G, Heitz PU. Pancreatic endocrine tumors. Pathol Res Prac. 1998;183:155–68.

    Google Scholar 

  6. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Tumours of the endocrine organs. WHO classification of tumors. Lyon: IARC Press; 2004.

    Google Scholar 

  7. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323–33.

    PubMed  CAS  Google Scholar 

  8. Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, et al. Nonfunctioning islet cell carcinoma of the pancreas. Surgery. 1993;114:1175–82.

    PubMed  CAS  Google Scholar 

  9. Gullo L, Migliori M, Falconi M, Pederzoli P, Bettini R, Casadei R, et al. Nonfunctional pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol. 2003;98:2435–9.

    Article  PubMed  Google Scholar 

  10. Nakao A. Pancreatic head resection with segmental duodenectomy and preservation of the gastroduodenal artery. Hepatogastroenterology. 1998;45:533–5.

    PubMed  CAS  Google Scholar 

  11. Procacci C, Carbognin G, Accordini S, Biasiutti C, Bicego E, Romano L, et al. Nonfunctional endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol. 2001;11:1175–83.

    Article  PubMed  CAS  Google Scholar 

  12. Sugiyama M, Abe N, Izumisato Y, Yamaguchi Y, Yamato T, Tokuhara M, et al. Differential diagnosis of benign versus malignant nonfunctioning islet cell tumors of the pancreas: the roles of EUS and ERCP. Gastrointest Endosc. 2002;55:115–9.

    Article  PubMed  Google Scholar 

  13. Klöppel G, Schroder S, Heitz PU. Histopathology and immunopathology of the pancreatic endocrine tumors. In: Mignon M, Jensen RT, editors. Endocrine tumors of the pancreas. Recent advances in research and management. Basel: Karger; 1995. p. 99–120.

    Google Scholar 

  14. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422–7.

    Article  PubMed  CAS  Google Scholar 

  15. Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M, Gimm O. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28:1248–60.

    Article  PubMed  Google Scholar 

  16. Bartch DK, Langer P, Wild A, Schilling T, Celik I, Rothmund M, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery. 2000;128:958–66.

    Article  Google Scholar 

  17. Solorzano CC, Lee JE, Pisters PWT, Vauthey JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130:1078–85.

    Article  PubMed  CAS  Google Scholar 

  18. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776–85.

    Article  PubMed  Google Scholar 

  19. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057–65.

    Article  PubMed  Google Scholar 

  20. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery. 2003;133:375–82.

    Article  PubMed  Google Scholar 

  21. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37.

    Article  PubMed  Google Scholar 

  22. McEntee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990;108:1091–6.

    PubMed  CAS  Google Scholar 

  23. Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000–4.

    Article  PubMed  Google Scholar 

  24. Ho AS, Picus J, Darcy MD, Gould JE, Pilgram TK, Brown DB. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. Am J Roentgenol. 2007;188:1201–7.

    Article  Google Scholar 

  25. Wessels FJ, Schell SR. Radiofrequency ablation treatment of refractory carcinoid hepatic metastases. J Surg Res. 2001;95:8–12.

    Article  PubMed  CAS  Google Scholar 

  26. Moertel CG, Lefkopould M, Lipsitz S, Hahn RG. Streptozocin–doxorubicin, streptozocin–fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23.

    PubMed  CAS  Google Scholar 

  27. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12:1139–43.

    Article  PubMed  CAS  Google Scholar 

  28. Arnold R, Rinke A, Schmidt Ch, Hofbauer L. Endocrine tumors of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol. 2005;19:649–56.

    Article  PubMed  CAS  Google Scholar 

  29. Bajetta E, Rimassa L, Carnaghi C, Seregni E, Ferrari L, Bartolomeo M, et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer. 1998;83:372–8.

    Article  PubMed  CAS  Google Scholar 

  30. Saltz L, Trochanowski B, Buckley M, Heffernan B, Niedzwiecki D, Tao Y, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72:244–8.

    Article  PubMed  CAS  Google Scholar 

  31. Di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, et al. ITMO Association. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer. 1996;77:402–8.

    Article  PubMed  CAS  Google Scholar 

  32. Fjällskog ML, Sundin A, Westlin JE, Öberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol. 2002;19:35–42.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan

    Naohiro Nomura, Tsutomu Fujii, Naohito Kanazumi, Shin Takeda, Shuji Nomoto, Hideki Kasuya, Hiroyuki Sugimoto, Suguru Yamada & Akimasa Nakao

Authors
  1. Naohiro Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsutomu Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naohito Kanazumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shin Takeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuji Nomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hideki Kasuya
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiroyuki Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Suguru Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Akimasa Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naohiro Nomura.

About this article

Cite this article

Nomura, N., Fujii, T., Kanazumi, N. et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg 16, 639–647 (2009). https://doi.org/10.1007/s00534-009-0099-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00534-009-0099-1

Keywords

Search

Navigation